HomeComparePSYGF vs EPRT

PSYGF vs EPRT: Dividend Comparison 2026

PSYGF yields 1574.80% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSYGF wins by $1094146078.80M in total portfolio value
10 years
PSYGF
PSYGF
● Live price
1574.80%
Share price
$0.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1094146078.86M
Annual income
$972,648,549,767,836.50
Full PSYGF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — PSYGF vs EPRT

📍 PSYGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSYGFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSYGF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSYGF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSYGF
Annual income on $10K today (after 15% tax)
$133,858.27/yr
After 10yr DRIP, annual income (after tax)
$826,751,267,302,661.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, PSYGF beats the other by $826,751,267,291,746.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSYGF + EPRT for your $10,000?

PSYGF: 50%EPRT: 50%
100% EPRT50/50100% PSYGF
Portfolio after 10yr
$547073039.46M
Annual income
$486,324,274,890,338.60/yr
Blended yield
88.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

PSYGF
No analyst data
Altman Z
-61.3
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSYGF buys
0
EPRT buys
0
No recent congressional trades found for PSYGF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSYGFEPRT
Forward yield1574.80%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$1094146078.86M$63.4K
Annual income after 10y$972,648,549,767,836.50$12,840.73
Total dividends collected$1085342975.29M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PSYGF vs EPRT ($10,000, DRIP)

YearPSYGF PortfolioPSYGF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$168,180$157,480.31$11,205$505.18+$157.0KPSYGF
2$2,655,195$2,475,241.96$12,672$682.46+$2.64MPSYGF
3$39,363,107$36,522,048.09$14,490$930.48+$39.35MPSYGF
4$548,134,593$506,016,068.87$16,786$1,282.69+$548.12MPSYGF
5$7,171,846,637$6,585,342,622.60$19,753$1,791.56+$7171.83MPSYGF
6$88,200,293,754$80,526,417,852.20$23,677$2,541.64+$88200.27MPSYGF
7$1,019,911,005,360$925,536,691,043.00$29,008$3,672.99+$1019910.98MPSYGF
8$11,093,656,198,301$10,002,351,422,566.60$36,463$5,425.08+$11093656.16MPSYGF
9$113,549,092,609,754$101,678,880,477,571.69$47,238$8,221.57+$113549092.56MPSYGF
10$1,094,146,078,860,274$972,648,549,767,836.50$63,385$12,840.73+$1094146078.80MPSYGF

PSYGF vs EPRT: Complete Analysis 2026

PSYGFStock

Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.

Full PSYGF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this PSYGF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSYGF vs SCHDPSYGF vs JEPIPSYGF vs OPSYGF vs KOPSYGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.